A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Oct 2017
At a glance
- Drugs Collagenase clostridium histolyticum (Primary)
- Indications Cellulite
- Focus Therapeutic Use
- Sponsors Endo Pharmaceuticals
- 16 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 15 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 15 Jun 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.